Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/15/2005WO2005118070A1 Therapy for multiple sclerosis
12/15/2005WO2005118009A2 Transdermal delivery system for treatment of cognitive disorders
12/15/2005WO2005117981A1 Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
12/15/2005WO2005117980A1 Method for treating abnormal cell growth
12/15/2005WO2005117968A2 Compositions and methods comprising an egfl7 antagonist for modulating vascular development
12/15/2005WO2005117954A2 Compositions and methods for treatment of neovascular diseases
12/15/2005WO2005117935A1 Multiple agent therapy for sexual dysfunction
12/15/2005WO2005117924A1 Compositions and methods using same for treating neurodegenerative disorders
12/15/2005WO2005117916A1 Treatment with cisplatin and an egfr-inhibitor
12/15/2005WO2005117915A1 Treatment with oxaliplatin and an egfr-inhibitor
12/15/2005WO2005117913A2 Ozonized pharmaceutical composition and method
12/15/2005WO2005117912A1 Methods for treating bleeding disorders using sulfated polysaccharides
12/15/2005WO2005117911A2 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
12/15/2005WO2005117910A2 Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
12/15/2005WO2005117909A2 Kinase modulators and methods of use
12/15/2005WO2005117908A2 Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases
12/15/2005WO2005117907A2 P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
12/15/2005WO2005117906A1 Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol)
12/15/2005WO2005117905A2 Systems and methods for treating panic attacks
12/15/2005WO2005117904A2 Phosphonate analogs of hiv integrase inhibitor compounds
12/15/2005WO2005117903A1 Treatment of cancer in pediatric patients
12/15/2005WO2005117902A1 Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis
12/15/2005WO2005117901A1 Oral formulations of paricalcitol
12/15/2005WO2005117900A1 Use of a detergent for the non-surgical removal of fat
12/15/2005WO2005117899A1 Pharmaceutical composition comprising tibolone and process for procuding the same
12/15/2005WO2005117898A1 Compositions and methods for treatment of premenstrual dysphoric disorder
12/15/2005WO2005117897A2 Hepoxilins and modulators of ichthyin for treatment skin disorders
12/15/2005WO2005117896A1 Formulations containing fasudil, a matrix and an envelope
12/15/2005WO2005117895A2 Compositions comprising meloxicam
12/15/2005WO2005117894A1 Leptomycin compounds
12/15/2005WO2005117893A2 Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors
12/15/2005WO2005117892A1 Treatment of lymphoma using 10-propargyl-10-deazaaminopterin and gemcitabine
12/15/2005WO2005117891A1 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
12/15/2005WO2005117890A2 Thienopyrimidines and thiazolopyrimidines for use in medicine
12/15/2005WO2005117889A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic
12/15/2005WO2005117888A1 Combination product comprising src kinase inhibitor azdo530 and an antioestrogen or egfr-tk-inhibitor
12/15/2005WO2005117887A1 Treatment with gemcitabine and an egfr-inhibitor
12/15/2005WO2005117886A1 Adhesive patch
12/15/2005WO2005117885A1 Use of imatinib to treat liver disorders and viral infections
12/15/2005WO2005117884A1 Methods for treating a mammal before, during and after cardiac arrest
12/15/2005WO2005117883A1 Modulators of muscarinic receptors
12/15/2005WO2005117882A2 Hydroxamic acid derivatives as metalloprotease inhibitors
12/15/2005WO2005117880A2 Methods for treating anxiety disorders and related article of manufacture
12/15/2005WO2005117878A1 Irinotecan preparation
12/15/2005WO2005117877A1 Treatment with irinotecan (cpt-11) and an egfr-inhibitor
12/15/2005WO2005117876A1 Dual small molecule inhibitors of cancer and angiogenesis
12/15/2005WO2005117875A1 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
12/15/2005WO2005117874A1 MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR THE INHIBITION OF BETA-AMYLOID (Aß40 AND Aß42) -GENERATION
12/15/2005WO2005117873A2 Compositions containing opioid antagonists
12/15/2005WO2005117872A2 Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
12/15/2005WO2005117871A2 Pharmaceutical compositions for the treatment of pruritus
12/15/2005WO2005117870A2 Combination of proton pump inhibitor, buffering agent, and prokinetic agent
12/15/2005WO2005117869A1 Combinations comprising (s)-amlodipine and a cholesteryl ester transfer protein inhibitor, and methods for reducing hypertension
12/15/2005WO2005117868A1 Tetrahydrocarboline antiviral agents
12/15/2005WO2005117867A2 Monocyclic heterocycles as kinase inhibitors
12/15/2005WO2005117864A1 Combination product comprising anastrozole and a dual prenyl transferase inhibitor
12/15/2005WO2005117863A2 Non-steroid anti-inflammatory agents with vitamins, minerals, and dietary supplements for the prevention and treatment of primary, secondary and tertiary cancer
12/15/2005WO2005117862A1 Treatment of urinary conditions including incontinence
12/15/2005WO2005117861A1 Use of organic compounds
12/15/2005WO2005117860A1 Method of treating and preventing arthritis, cutaneous and cardiovascular inflammatory-related diseases using nicotinic receptor agonists
12/15/2005WO2005117859A2 Methods of diagnosing cardiovascular disease
12/15/2005WO2005117858A2 Compositions comprising nebivolol
12/15/2005WO2005117857A1 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
12/15/2005WO2005117856A1 Use of furan alkyl for preparing an antidiabetic drug
12/15/2005WO2005117855A1 Drug for prevention or treatment of diabetes
12/15/2005WO2005117854A2 Aryl ketone compounds and compositions for delivering active agents
12/15/2005WO2005117853A1 Therapeutic agent for hyperlipemia and therapeutic agent for diabetes
12/15/2005WO2005117852A1 Composition for treatment of a hydrofluoric acid burn
12/15/2005WO2005117851A1 Prevention, treatment, and amelioration of radiation induced enteritis
12/15/2005WO2005117850A1 Partially-fluorinated ethers, compositions and uses thereof, for long-term tamponade in the eye
12/15/2005WO2005117849A1 Diarylalkanes as potent inhibitors of binuclear enzymes
12/15/2005WO2005117848A2 Vascular targets for detecting, imaging and treating neoplasia or neovasculature
12/15/2005WO2005117847A2 Methods and compounds for the treatment of neoplasms
12/15/2005WO2005117846A2 Ice inhibitors for the treatment of autoinflammatory diseases
12/15/2005WO2005117845A1 Oral preparations and process for production thereof
12/15/2005WO2005117843A2 Sustained release preparations
12/15/2005WO2005117841A1 Coated tablet formulation and method
12/15/2005WO2005117840A1 Stable pharmaceutical compositions comprising pulverized granules of nateglinide of form b
12/15/2005WO2005117839A1 Preparation of stable paroxetine hci er tablets using a melt granulation process
12/15/2005WO2005117838A1 Stable oral pharmaceutical compositions of buprenorphine and derivatives
12/15/2005WO2005117837A1 Process for preparation of amorphous form of a drug
12/15/2005WO2005117831A1 Injectable pharmaceutical suspension comprising posaconazole
12/15/2005WO2005117829A2 Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
12/15/2005WO2005117811A2 Physiological cooling compositions
12/15/2005WO2005117753A1 Medical devices composed of porous metallic materials for delivering biolgically active materials
12/15/2005WO2005117752A1 A coated medical device and method for making the same
12/15/2005WO2005117603A1 Pet food compositions and methods
12/15/2005WO2005117592A1 Treatment of dermatological conditions
12/15/2005WO2005117589A1 Synthesis of metabolically stable analgesics, pain medications and other agents
12/15/2005WO2005117585A1 Mixed co-crystals and pharmaceutical compositions comprising the same
12/15/2005WO2005117550A2 Composition and method for the treatment of tauopathies
12/15/2005WO2005117543A2 N-sulfonylcarboximidamide apoptosis promoters
12/15/2005WO2005107461A3 Modulating lymphatic function
12/15/2005WO2005105065A3 Thiazole-based nitric oxide donors for treating inflammatory bowel diseases
12/15/2005WO2005102359A8 Liposomal formulations of anthracycline agents and cytidine analogs
12/15/2005WO2005102323A3 Process of preparing esters and ethers of probucol and derivatives thereof
12/15/2005WO2005097768A3 Novel gamma secretase inhibitors
12/15/2005WO2005097763A3 1,3,4-oxadiazol-2-ones as ppar delta
12/15/2005WO2005097762A3 1,3,4-oxadiazol-2-ones as ppar delta modulators
12/15/2005WO2005097102A3 Method to treat chronic heart failure and/or elevated cholesterol levels
1 ... 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 ... 7860